Parabilis Medicines, Inc. Chief Medical Officer Mohammed Fawzi Benzaghou reported his initial beneficial ownership on Form 3, showing two stock option awards for common stock. One option covers 243,680 underlying shares at an exercise price of $3.14 per share, expiring on February 17, 2036.
The second option covers 357,398 underlying shares at an exercise price of $2.42 per share, expiring on September 10, 2035. Vesting is time-based: one grant vests 25% on September 2, 2026 with the rest monthly over 36 months, and the other vests in 48 equal monthly installments starting February 9, 2026, subject to continued service.
Parabilis Medicines, Inc. director Jake Simson has filed an initial Form 3 ownership report. This filing identifies him as a director of the company but, in the provided data, shows no reported transactions or specific equity holdings. It serves as a baseline disclosure of his insider status.
Parabilis Medicines, Inc. director Alexis Borisy filed an initial ownership report showing a direct holding of Series F Preferred Stock. Each share of this preferred stock is convertible into Common Stock on a 1 to 0.6498 basis at the holder’s option and has no expiration date. The filing notes that this preferred stock will automatically convert into 105,414 shares of Common Stock immediately prior to the closing of the company’s initial public offering and without any payment of additional consideration. The filing does not report any new purchase or sale, only the existing position.
Parabilis Medicines, Inc. Chief Financial Officer Thomas Rodolpho Kotarakos reported his existing stock option holdings in a Form 3. He holds options over 292,416 shares of common stock at an exercise price of $3.14 expiring on February 17, 2036, which are fully vested. He also holds options over 165,702 shares at $1.48 per share expiring on March 27, 2034, vesting in 48 equal monthly installments from January 1, 2024, and 48,736 shares at $4.82 per share expiring on December 18, 2031, vesting in 48 equal monthly installments from February 9, 2026. The filing reflects holdings only and does not show new purchases or sales.
Parabilis Medicines director Barbara Weber filed a Form 3 showing her stock option holdings. She reports options over 32,490 shares of common stock at an exercise price of $3.14 per share expiring on February 23, 2036, 16,245 shares at $4.82 expiring on May 12, 2031, 13,646 shares at $4.62 expiring on September 24, 2028, and 2,599 shares at $1.85 expiring on December 14, 2027. One option grant is fully vested, and another will vest in 48 equal monthly installments starting on February 24, 2026, conditioned on her continued service.
Parabilis Medicines, Inc. is launching an initial public offering of 33,333,334 shares of voting common stock. The estimated price range is $17.00 to $19.00 per share, and underwriters have a 5,000,000-share overallotment option. A concurrent Regeneron private placement is expected to add about $75.0 million at 90% of the IPO price.
Based on an assumed $18.00 price, Parabilis projects approximately $553.1 million in net IPO proceeds plus $75.0 million from the private placement, boosting pro forma cash to about $957.1 million. The company, a clinical-stage oncology-focused biopharma built around its Helicon peptide platform, plans to fund late-stage development of lead candidate zolucatetide and advance a broader pipeline, while remaining an emerging growth and smaller reporting company with considerable operating losses.
Parabilis Medicines, Inc. is launching an initial public offering of 25,000,000 shares of voting common stock, with an estimated price range of $17.00 to $19.00 per share, and a planned Nasdaq Global Market listing under the symbol PBLS.
The company is a clinical-stage biopharmaceutical developer of “Helicons,” stabilized helical peptides designed to drug historically undruggable intracellular protein targets. Its lead candidate, zolucatetide, targets the Wnt/β‑catenin pathway and has shown tumor reductions in desmoid tumors and activity across multiple Wnt/β‑catenin–driven cancers.
Parabilis estimates $413.6 million in net IPO proceeds (at a midpoint price of $18.00), plus a $75.0 million concurrent private placement to Regeneron at 90% of the IPO price. As of March 31, 2026, it held $329.0 million in cash and cash equivalents and reported a 2025 net loss of $145.9 million, reflecting heavy R&D investment and no product revenue.
Parabilis Medicines, Inc. filed Amendment No. 1 to its registration statement on Form S-1. The amendment is described as being filed solely to add and update certain exhibits, including equity incentive plans, a stock option and incentive plan, an employee stock purchase plan, key licensing and loan agreements, and executive and director compensation arrangements. The company states that the remainder of the registration statement is unchanged and has been omitted from this amendment.
Parabilis Medicines, Inc. is a clinical-stage biopharmaceutical company planning an initial public offering of voting common stock on the Nasdaq Global Market under the symbol PBLS, alongside a concurrent $75.0 million private placement to Regeneron at 90% of the IPO price.
The company is developing Helicons, stabilized helical peptides designed to drug historically undruggable intracellular targets. Lead candidate zolucatetide targets the Wnt/β‑catenin pathway and has treated over 150 patients. In desmoid tumors, all 25 response‑evaluable patients showed tumor reductions and 74% of 19 patients with at least two post‑baseline scans achieved an objective response.
Parabilis is also studying zolucatetide in familial adenomatous polyposis, hepatocellular carcinoma, additional rare Wnt/β‑catenin–driven tumors, and colorectal cancer, and advancing ERG and ARON degraders for prostate cancer. The company reported a net loss of $145.9 million in 2025 and had cash and cash equivalents of $329.0 million and an accumulated deficit of $586.8 million as of March 31, 2026. Proceeds from the IPO and private placement, plus a $50.0 million upfront Regeneron payment, are earmarked mainly for zolucatetide clinical programs, pipeline advancement, platform development, and general corporate purposes.